Physician profile
Arslan Johnghar
NPI 1568755700
$3,469.49
in general payments reported to CMS, 2019-2025
12 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2021: $1,265 · 2022: $26.15 · 2023: $136 · 2024: $1,329 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062 · Travel and Lodging: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.75 |
| Travel and Lodging | $825.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,489.86 | 2021-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $1,271.86 | 2019-2024 | Ingevity Mri |
| Novartis Pharmaceuticals Corporation | $192.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.87 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $96.80 | 2019-2025 | Camzyos |
| Edwards Lifesciences Corporation | $82.27 | 2025 | |
| Pfizer INC. | $65.31 | 2019-2023 | |
| Becton, Dickinson and Company | $47.22 | 2019 | |
| Heartflow, INC. | $36.02 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.07 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arslan Johnghar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.